Home About Us FAQ Policies Contact Site Map
 
 
QUICK SEARCH
   Advanced Search
 
 
 
   
 
Stay updated on your favorite report topics! We are adding hundreds of new reports daily. Receive email alerts when those reports affect you!

Stay on top of your industry.
  
 

Molecular Diagnostics Markets
Product Type: Market Research Report Publication Date: Sep 01, 2008
 
Request a sample from "The Infoshop", another service of Global Information.

SUMMARY

The technologies that constitute molecular diagnostics-first-generation amplification, DNA probes, fluorescent in situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors, and molecular labels-are influencing the discovery of therapeutic molecules, the screening and diagnosis of patients, and the optimization of drug therapy. In the past few years, this rapidly evolving field has seen several fascinating developments. This TriMark Publications report describes the specific market segment of the in vitro diagnostics market known as molecular diagnostics and includes all of the generally accepted clinical analytical activities in use today. It examines the prevalent clinical-measurement devices, as well as their reagents and supplies as utilized in hospitals, clinics, large reference laboratories and doctor's offices. Diagnostic tests marketed primarily as over-the-counter are generally not included in this report, although there is inevitably some overlap. The main objectives of this analysis are: 1) identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing; 2) obtaining a complete understanding of the chief molecular diagnostics tests-i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic-from their basic principles to their applications; 3) discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; and 4) focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts.

By Purchasing This Report You Will Have:

  • An improved understanding of the current state and future of the molecular diagnostics market.
  • The latest information on the leading companies engaged in research and development and products in the pipeline.
  • The leading perspective of recent imaging developments and revelations.
  • Knowledge of the molecular diagnostics market as an area of growth, research and investment.

This Report Will Cover the Following Molecular Diagnostics Technologies:

  • Nucleic acid test applications.
  • Blood testing and infectious diseases.
  • Diagnostic testing using DNA.
  • Cancer detection using PCR.
  • Microbiology testing.
  • Blood screening.
  • SNPs in clinical diagnostics.
  • Industrial testing and food diagnostics.
  • Forensics market.
  • Bioterrorism and molecular diagnostics.
  • Cystic fibrosis testing.
  • HLA sequencing-based typing kits
  • Cytogenetic testing.
  • Developments in biochips for clinical applications.
  • Pharmacogenomics.

TABLE OF CONTENTS

1. Overview

  • 1.1 Statement of Report
  • 1.2 About This Report
  • 1.3 Scope of the Report
  • 1.4 Objectives
  • 1.5 Methodology
  • 1.6 Executive Summary

2. Introduction to Molecular Diagnostics and PCR Technology

  • 2.1 Science Overview: Introduction to Genomics and Its Opportunity
  • 2.2 Impact of the Human Genome Project on Molecular Diagnostics
  • 2.3 Considerations for Molecular and Clinical Diagnosis
  • 2.4 Molecular Diagnosis in the Post-Genomic Era
  • 2.5 Advances in Molecular Diagnostics Technologies
  • 2.6 Genetic Variability and Disease
  • 2.7 Major Technology Platforms
    • 2.7.1 Gene-based Amplification Technologies
    • 2.7.2 Detection of Amplified Gene Products
    • 2.7.3 Target-Based Gene Amplification
      • 2.7.3.1 Polymerase Chain Reaction
      • 2.7.3.2 Real-time PCR
      • 2.7.3.3 Nucleic Acid Sequence-Based Amplification
    • 2.7.4 Probe-Based Amplification
      • 2.7.4.1 Ligase Chain Reaction
      • 2.7.4.2 Strand Displacement Amplification
      • 2.7.4.3 Qβ-replicase Amplified Probe Assay
    • 2.7.5 Signal-Based Amplification
      • 2.7.5.1 Branched DNA (bDNA)
    • 2.7.6 Other Gene Amplification Technologies
      • 2.7.6.1 Immuno-PCR
      • 2.7.6.2 Bio-Barcode Assay

3. Nucleic Acid Test Applications

  • 3.1 Blood Testing and Infectious Diseases
    • 3.1.1 Molecular Diagnostics Market
      • 3.1.1.1 Methods for DNA Detection and Gene Sequencing
      • 3.1.1.2 Products and Applications
      • 3.1.1.3 Oncology
    • 3.1.2 SNPs and Genes: Medical Utility (Clinical Applications)
      • 3.1.2.1 Clinical Application Initiatives
      • 3.1.2.2 A Sampling of Clinical Application Collaborations
      • 3.1.2.3 Collaborative Relationships
  • 3.2 Diagnostic Testing Using DNA
    • 3.2.1 HIV
    • 3.2.2 Hepatitis Serologic Markers and Nucleic Acid Testing
      • 3.2.2.1 Hepatitis A Virus (HAV)
      • 3.2.2.2 Hepatitis B Virus (HBV)
      • 3.2.2.3 Hepatitis C Virus (HCV)
      • 3.2.2.4 Hepatitis D Virus (HDV)
      • 3.2.2.5 Hepatitis E Virus (HEV)
      • 3.2.2.6 HBV/HCV Viral Load and Drug Resistance
    • 3.2.3 Severe Acute Respiratory Syndrome (SARS)
      • 3.2.3.1 New Approach to Diagnosing Avian Influenza
      • 3.2.3.2 Microarray or DNA Chip-Based Tests
    • 3.2.4 Cancer Detection Using PCR
      • 3.2.4.1 Lung Cancer
      • 3.2.4.2 Oral Cancer
      • 3.2.4.3 Prostate Cancer
      • 3.2.4.4 Chronic Myelogenous Leukemia
      • 3.2.4.5 Malignant Gliomas
      • 3.2.4.6 Colorectal Cancer
      • 3.2.4.7 Breast Cancer
      • 3.2.4.8 Bladder Cancer
    • 3.2.5 Microbiology Testing
      • 3.2.5.1 Chlamydia
      • 3.2.5.2 Gonorrhea
      • 3.2.5.3 Tuberculosis
      • 3.2.5.4 Group B Streptococcus
      • 3.2.5.5 Pathogenic Enteric Bacteria
      • 3.2.5.6 Bordetella pertussis
      • 3.2.5.7 Legionella Pneumophila
      • 3.2.5.8 Peridontal Bacteria
      • 3.2.5.9 Pneumocystis Carinii
      • 3.2.5.10 Methicillin-resistant Staphylococcus Aureus
    • 3.2.6 Blood Screening
  • 3.3 SNPs in Clinical Diagnostics
    • 3.3.1 Functional Genomics
    • 3.3.2 Paternity Testing
  • 3.4 Industrial Testing and Food Diagnostics
    • 3.4.1 The Market
    • 3.4.2 Detection of H. pylori by PCR
    • 3.4.3 Detection of E. coli 0157
    • 3.4.4 Detection of Enteric Viruses
  • 3.5 Forensics Market
    • 3.5.1 Isolation of DNA for PCR Profiling
    • 3.5.2 Analysis by PCR-Based DNA Typing
    • 3.5.3 Rapid Isolation of DNA for RFLP and PCR
    • 3.5.4 DNA for PCR-STR Typing
  • 3.6 Bioterrorism and Molecular Diagnostics
    • 3.6.1 Introduction
      • 3.6.1.1 Current Biological Threat Detection Systems
      • 3.6.1.2 Use of DNA Microarrays and Biochips for Gene Expression Profiles in BWA
      • 3.6.1.3 Advantages and Disadvantages of Host Gene Expression Profiling as a Biothreat Detection System
    • 3.6.2 Biological Warfare Agents
      • 3.6.2.1 Anthrax
      • 3.6.2.2 Botulinum Toxin
      • 3.6.2.3 Ricin
      • 3.6.2.4 IVD Industry and Bioterrorism Preparedness
        • 3.6.2.4.1 Brucellosis
        • 3.6.2.4.2 Cholera
      • 3.6.2.5 Rapid Lateral Flow Immunoassays
      • 3.6.2.6 Biosensors
        • 3.6.2.6.1 Antibody and Synthetic Receptor-Based Sensors
        • 3.6.2.6.2 DNA Sensors
        • 3.6.2.6.3 Reagentless Sensors
    • 3.6.3 Anthrax in Clinical Samples
      • 3.6.3.1 Overview of Anthrax and Its Infectivity
      • 3.6.3.2 Rapid Tests
        • 3.6.3.2.1 PCR Tests
  • 3.7 Cystic Fibrosis Testing
  • 3.8 HLA Sequencing-Based Typing Kits
  • 3.9 Cytogenetic Testing
    • 3.9.1 Hereditary Hemochromatosis
    • 3.9.2 Apolipoprotein E (ApoE) Genotyping
    • 3.9.3 Fragile X Syndrome
    • 3.9.4 Methylenetetrahydrofolate Reductase (MTHFR) Carrier Testing
  • 3.10 Developments in Biochips for Clinical Applications
    • 3.10.1 Roche AmpliChip Microarray
    • 3.10.2 Breast Cancer DNA Chips
    • 3.10.3 eSensor DNA Detection System
  • 3.11 Pharmacogenomics
    • 3.11.1 Coumadin
  • 3.12 Thrombic Disorders

4. Trends in Molecular Diagnostics

  • 4.1 Pharmacogenomics
    • 4.1.1 The Market
      • 4.1.1.1 Oncology
      • 4.1.1.2 Toxicogenomics
    • 4.1.2 Market Influences and Forecast
  • 4.2 DNA Microarrays
    • 4.2.1 Techniques
    • 4.2.2 The Market
    • 4.2.3 Identification of Sequence SNPs
    • 4.2.4 Determining Gene Expression Levels
      • 4.2.4.1 Hybridization Tests
      • 4.2.4.2 Oligonucleotide Probes
    • 4.2.5 Molecular Diagnostics Entry into Point-of-Care Testing
  • 4.3 Emerging Markets of DNA Arrays
    • 4.3.1 Pharmacogenomics
    • 4.3.2 Adoption of Amplified Screening Technology
    • 4.3.3 Advances in Automated Testing
    • 4.3.4 Increased Focus on Safety of Blood Supply
    • 4.3.5 Development of Emerging Markets for NAT Technology
    • 4.3.6 Cancer
    • 4.3.7 Human Leukocyte Antigen Typing
    • 4.3.8 Neonatal Screening
  • 4.4 Drivers and Restraints
  • 4.5 Market Forecast
  • 4.6 Business Trends in the Industry
    • 4.6.1 Molecular Diagnostics Industry Trends
      • 4.6.1.1 Adoption of Amplified Screening Technology
      • 4.6.1.2 Advances in Automated Testing
      • 4.6.1.3 Responsiveness to Newly Emerging Threats
      • 4.6.1.4 Increased Focus on Safety of Blood Supply
      • 4.6.1.5 Growth in Viral Load Testing
      • 4.6.1.6 Development of Emerging Markets for NAT Technology
      • 4.6.1.7 Improvements in Detection Technologies
    • 4.6.2 Pharmaceutical Industry Trends
    • 4.6.3 Acquisitions, License Agreements and Partnerships
    • 4.6.4 Ethical, Legal and Social Issues Related to the Use of Genetic Information
    • 4.6.5 Regulatory Issues
    • 4.6.6 Reimbursement Issues
      • 4.6.6.1 Cystic Fibrosis
      • 4.6.6.2 Viral Load Testing
      • 4.6.6.3 NMP22
      • 4.6.6.4 iFOB Reimbursement

5. Molecular Diagnostics Automated Instrumentation Approved for Market by the FDA

  • 5.1 Gene Expression Profiling
  • 5.2 Proteomic Multiplex Assays
  • 5.3 Solution-Phase Multiplexing
  • 5.4 RNA Interference (RNAi)
    • 5.4.1 Role of RNAi in Drug Target Validation
    • 5.4.2 Other Companies Involved in the RNAi Market
  • 5.5 DNA Tags

6. Market Trends and Forecasts

  • 6.1 Market Dynamics
    • 6.1.1 Technological Perspective on Molecular Diagnostics
    • 6.1.2 Molecular Diagnostics Market Opportunities
    • 6.1.3 Market Forces
      • 6.1.3.1 Adoption of Amplified Screening Technology
      • 6.1.3.2 Advances in Automated Testing
      • 6.1.3.3 Responsiveness to Newly Emerging Threats
      • 6.1.3.4 Increased Focus on Safety of Blood Supply
      • 6.1.3.5 Growth in Viral Load Testing
      • 6.1.3.6 Development of Emerging Markets for NAT Technology
      • 6.1.3.7 Improvements in Detection Technologies
  • 6.2 Future Considerations for Molecular Diagnosis
  • 6.3 Role of Genomics in Transforming Pharmaceutical R&D
  • 6.4 Cancer Markers
  • 6.5 Cytology Markers
  • 6.6 RNA Detection
  • 6.7 Diagnosis of Inherited Disease
  • 6.8 Ethical Considerations
  • 6.9 NAT and Personalized Medicine
  • 6.10 Five Molecular Diagnostics Growth Areas
  • 6.11 Specific Commercial Nucleic Acid Probes
  • 6.12 Novel Amplification Techniques in the Market
  • 6.13 Ramification Amplification Method (RAM)
  • 6.14 Invader Assays/Third Wave Technologies
  • 6.15 Molecular Beacons
  • 6.16 HLA Sequencing-Based Typing Kits
  • 6.17 Prenatal Diagnosis
  • 6.18 Newborn Screening
  • 6.19 NAT and Preventive Medicine: NAT-Based Assays
  • 6.20 Prenatal and Pre-implantation Diagnosis
  • 6.21 FISH-Based Tests on Fetal Cells
  • 6.22 Companion Therapeutic/Diagnostic Approach
  • 6.23 Sample Preparation Market

7. Corporate Directory

  • 7.1 Abbott Laboratories
  • 7.2 Affymetrix
  • 7.3 Agendia
  • 7.4 Agilent Technologies
  • 7.5 Ambion
  • 7.6 Applied Biosystems Group
  • 7.7 Beckman Coulter
  • 7.8 BioGenex
  • 7.9 bioMérieux
  • 7.10 Bio-Rad Laboratories
  • 7.11 Biotage
  • 7.12 Biotest
  • 7.13 Caliper Life Sciences
  • 7.14 Celera Group
  • 7.15 Cellomics
  • 7.16 Cepheid
  • 7.17 Chiron (Novartis)
  • 7.18 Ciphergen Biosystems
  • 7.19 CuraGen
  • 7.20 Cytocell Technologies
  • 7.21 Dako A/S (formerly DakoCytomation A/S)
  • 7.22 DiaDexus
  • 7.23 Digene
  • 7.24 Enzo Biochem
  • 7.25 Epigenomics
  • 7.26 Epoch Biosciences
  • 7.27 EraGen Biosciences
  • 7.28 Eurogentec
  • 7.29 Exiqon
  • 7.30 Gene Link
  • 7.31 Gene Logic
  • 7.32 GeneOhm Sciences
  • 7.33 Genisphere
  • 7.34 Gen-Probe
  • 7.35 Genzyme
  • 7.36 Hamilton Thorne Biosciences
  • 7.37 ID Biomedical
  • 7.38 Illumina
  • 7.39 Incyte
  • 7.40 Innogenetics
  • 7.41 Interleukin Genetics
  • 7.42 Invitrogen
  • 7.43 Kreatech Biotechnology
  • 7.44 LabCorp
  • 7.45 LI-COR Biosciences
  • 7.46 Matritech
  • 7.47 Meridian Bioscience
  • 7.48 Monogram Biosciences
  • 7.49 Motorola
  • 7.50 MWG Biotech
  • 7.51 Myriad Genetics
  • 7.52 Nanogen
  • 7.53 Nanosys
  • 7.54 NimbleGen Systems
  • 7.55 Nuvelo
  • 7.56 Nymox Pharmaceutical
  • 7.57 Orchid BioSciences
  • 7.58 Orchid Cellmark
  • 7.59 Organon International
  • 7.60 Ortho-Clinical Diagnostics
  • 7.61 Ostex International
  • 7.62 PerSeptive Biosystems
  • 7.63 PharMingen
  • 7.64 PPD
  • 7.65 PPGx (DNA Sciences Laboratories)
  • 7.66 Prodesse
  • 7.67 Professional Genetics Laboratory
  • 7.68 Promega
  • 7.69 QIAGEN
  • 7.70 Quantum Biotechnologies
  • 7.71 Quidel
  • 7.72 Response Biomedical
  • 7.73 Roche Diagnostics
  • 7.74 Siemens
  • 7.75 Sequenom
  • 7.76 SurModics
  • 7.77 Tepnel Life Sciences
  • 7.78 Thermo Fisher Scientific
  • 7.79 Third Wave Technologies
  • 7.80 Tm Bioscience
  • 7.81 Visible Genetics
  • 7.82 VisiGen Biotechnologies
  • 7.83 Vysis
  • 7.84 Alternative Sequencing Companies
  • 7.84.1 Callida Genomics, Inc.
  • 7.84.2 Mobious Genomics, Ltd.
  • 7.84.3 Perlegen Sciences, Inc.
  • 7.84.4 Solexa, Ltd.
  • 7.84.5 U.S. Genomics, Inc.

8. Market Overview

  • 8.1 Snapshot of Molecular Diagnostics Industry Structure
  • 8.2 Global Molecular Diagnostics Testing Market
  • 8.3 U.S. Molecular Diagnostics Testing Market
  • 8.4 European Molecular Diagnostics Market
  • 8.5 Japanese Molecular Diagnostics Testing Market
  • 8.6 Overview of the European Molecular Diagnostics Country Markets
    • 8.6.1 France
    • 8.6.2 Germany
    • 8.6.3 The United Kingdom
    • 8.6.4 Italy
    • 8.6.5 Spain
  • Appendix 1: Biowarfare Agents

LIST OF FIGURES

  • Figure 2.1: Segment of Double-Stranded DNA Showing the Base-Pair Relationship
  • Figure 3.1: Applications of Molecular Diagnostics Technology Platforms
  • Figure 3.2: Overall Structure of Nucleic Acid Testing Market
  • Figure 3.3: Serologic and Clinical Course of Acute HBV Infection
  • Figure 3.4: Primary Causes of Chronic Liver Disease
  • Figure 3.5: Combination Therapy in Typical HCV Infection
  • Figure 3.6: Time Course of Markers in Typical HCV Infection
  • Figure 3.7: Bacillus anthracis
  • Figure 8.1: Molecular Diagnostics Market Segmentation
  • Figure 8.2: Molecular Diagnostics Market Segmentation by Technology
  • Figure 8.3: Breakout of the Molecular Diagnostics Marketplace
  • Figure 8.4: U.S. Molecular Diagnostics Market Segments 2007

LIST OF TABLES

  • Table 3.1: Global Market for Molecular Diagnostics Testing, 2000 to 2012
  • Table 3.2: U.S. Market for Molecular Diagnostics Testing, 2004 to 2012
  • Table 3.3: Global Market for Nucleic Acid Testing, 2000 to 2012
  • Table 3.4: Summary of Molecular Diagnostics Testing
  • Table 3.5: Annual U.S. Market for DNA Probe Diagnostics, 1998 to 2012
  • Table 3.6: Annual Global Market for DNA Probe Diagnostics, 1998 to 2009
  • Table 3.7: Estimated Market Share of Major Competitors in U.S. DNA/PCR Kit Research Market
  • Table 3.8: Estimated Market Share of Major Competitors in U.S. DNA/PCR Kit Diagnostics Market
  • Table 3.9: Roche PCR Licenses
  • Table 3.10: DNA Probe Market Segments in the U.S.
  • Table 3.11: Companies Marketing Products Using DNA Probes
  • Table 3.12: Companies Marketing Multiple Products in Molecular Diagnostics Sector
  • Table 3.13: Global Sales of DNA Probe Kits, 1998 to 2005
  • Table 3.14: Companies Marketing DNA Detection Platforms
  • Table 3.15: Companies Marketing Genotyping Technologies
  • Table 3.16: Companies Marketing Clinical Genotyping Technologies
  • Table 3.17: Summary of Assays for HIV Viral Load Testing
  • Table 3.18: Global Market for HIV Diagnostic Testing, 2000 to 2012
  • Table 3.19: U.S. Market for HIV Diagnostic Testing, 2000 to 2012
  • Table 3.20: Serologic Diagnosis of HBV Infections*
  • Table 3.21: Unusual HBV Serologic Profiles Requiring Further Evaluation
  • Table 3.22: Recommendations for HBV Diagnostic Testing
  • Table 3.23: Lower Detection Limits of HBV DNA Assays
  • Table 3.24: Recommendations for HCV Diagnostic Testing
  • Table 3.25: Important HCV Statistics
  • Table 3.26: Global Market for HAV Diagnostic Testing, 2000 to 2008
  • Table 3.27: U.S. Market for HAV Diagnostic Testing, 2000 to 2008
  • Table 3.28: Global Market for HBV Diagnostic Testing, 2000 to 2008
  • Table 3.29: U.S. Market for HBV Diagnostic Testing, 2000 to 2008
  • Table 3.30: Global Market for HCV Diagnostic Testing, 2000 to 2008
  • Table 3.31: U.S. Market for HCV Diagnostic Testing, 2000 to 2008
  • Table 3.32: Global Market for SARS Diagnostics Testing, 2002 to 2008
  • Table 3.33: U.S. Market for SARS Diagnostics Testing, 2002 to 2008
  • Table 3.34: Global Market for Molecular Diagnostics Cancer Testing, 2000 to 2008
  • Table 3.35: Annual Volume of NAT Infectious Disease Testing, 2000 to 2008
  • Table 3.36: Global Market Dollar Volume of NAT STD Testing, 2000 to 2008
  • Table 3.37: U.S. Market Dollar Volume of NAT STD Testing, 2000 to 2009
  • Table 3.38: U.S. Market Share of NAT STD Testing
  • Table 3.39: Global Market for Chlamydia Diagnostic Testing, 2000 to 2009
  • Table 3.40: U.S. Market for Chlamydia Diagnostic Testing, 2000 to 2009
  • Table 3.41: Global Market for Gonorrhea Diagnostic Testing, 2000 to 2008
  • Table 3.42: Global Market for TB Diagnostic Testing, 2000 to 2008
  • Table 3.43: Global Market for DNA Group B Streptococcus Diagnostic Testing, 2000 to 2009
  • Table 3.44: U.S. Market for Group B Streptococcus Diagnostic Testing, 2000 to 2009
  • Table 3.45: Gen-Probe Clinical Diagnostic Products for the Detection of Non-Viral Micro-organisms
  • Table 3.46: Global Market for Blood-Screening Diagnostic Testing, 2000 to 2008
  • Table 3.47: U.S. Market for Blood-Screening Diagnostic Testing, 2000 to 2008
  • Table 3.48: Leading Players in SNP Genotyping
  • Table 3.49: Global Market for SNP Genotyping, 2000 to 2011
  • Table 3.50: DNA-Analysis Market Competitors
  • Table 3.51: Leading Companies in Medical Utility of SNPs
  • Table 3.52: Competitors in the Field of Identity Genomics Testing
  • Table 3.53: U.S. Market for Food-Screening Diagnostic Testing Using Molecular Diagnostics Techniques, 2000 to 2008
  • Table 3.54: Methods for Detection of Salmonella in Food Using Molecular Diagnostics Methods
  • Table 3.55: U.S. Market for Forensic Diagnostics Testing, 2000 to 2010
  • Table 3.56: U.S. Market for Biological Threat Detection Testing, 2000 to 2010
  • Table 3.57: Biotest Reagents
  • Table 3.58: Variation of CF Carrier Risks by Ethnic Group
  • Table 3.59: Reasons for CF Testing
  • Table 3.60: Variation of CF Detection Rates by Ethnic Background
  • Table 3.61: Global Market for CF Diagnostic Testing, 2000 to 2008
  • Table 3.62: U.S. Market for CF Diagnostic Testing, 2000 to 2008
  • Table 3.63: Commercial CF-Screening Products
  • Table 3.64: Emerging CF-Screening Products
  • Table 3.65: CF Screening Technology Summary
  • Table 3.66: U.S. Market for HLA Type Testing, 2000 to 2008
  • Table 3.67: Competitors in HLA Testing
  • Table 3.68: U.S. Market for NAT Genetic-Disease Testing, 2000 to 2008
  • Table 3.69: Non-U.S. Market for NAT Genetic-Disease Testing, 2000 to 2008
  • Table 3.70: U.S. Market for NAT Cytogenetic-Disease Testing, 2000 to 2008
  • Table 3.71: Non-U.S. Market for NAT Cytogenetic-Disease Testing, 2000 to 2008
  • Table 3.72: Carrier Rates of Common HFE Mutations in Caucasians
  • Table 3.73: Results and Diagnosis for Fragile X Syndrome
  • Table 3.74: Principal Competitors in Pharmacogenetics R&D for Personalized Medicine
  • Table 3.75: Principal Competitors in Pharmacogenetics Patient Testing
  • Table 4.1: DNA-Sequencing Market Players
  • Table 4.2: Global Market for DNA Chips, 2000 to 2007
  • Table 4.3: Top Ten Companies for Molecular Diagnostics Patents
  • Table 6.1: Companies Licensed to Sell Custom Molecular Beacon Probes
  • Table 6.2: U.S. Sample Preparation Market, 2005 to 2012
  • Table 7.1: Products Marketed by Abbott in the Diagnostics Market
  • Table 7.2: Summary of Selected Affymetrix Expression-Profiling Customers
  • Table 7.3: PACE Product Sales as a Percentage of Total Company Revenue, 2000 to 2005
  • Table 7.4: Innogenetics HLA Products for Genetic Testing and Transplantation
  • Table 7.5: Nanogen Product Sales, 2000 to 2006
  • Table 7.6: Rarely-Expressed Genes as Therapeutic Product Candidates
  • Table 7.7: Roche Diagnostics Key Products
  • Table 7.8: Sales by Region
  • Table 7.9: Sales by Business Area
  • Table 7.10: Product Line Sales 2005
  • Table 7.11: Growth Drivers
  • Table 8.1: Number of Molecular Diagnostics Tests in the U.S., 2000 to 2008
  • Table 8.2: Global Molecular Diagnostics Testing Revenues, 2000 to 2012
  • Table 8.3: Global Distribution of Molecular Diagnostics Testing
  • Table 8.4: U.S. Molecular Diagnostics Testing Market, 2004 to 2012
  • Table 8.5: European Molecular Diagnostics Testing Market, 2005 to 2012
  • Table 8.6: Japanese Molecular Diagnostics Testing Market, 2005 to 2012

Molecular Diagnostics Markets

Publisher: Trimark Publications

Format Price Order
PDF by E-mail (Single User License) US $3400.00
PDF By E-mail (Unlimited User License) US $6800.00
All orders are processed by "www.the-infoshop.com". www.the-infoshop.com is another Global Information web site. This transfer is entirely safe.
Copyright© 2008 GII - All Rights Reserved.